Get the Stockscreener App
1.95
0.00%
0.00
InspireMD Inc. stock is traded at $1.95, with a volume of 58,531.
It is up +0.00% in the last 24 hours and up +8.94% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$1.95
Open:
$1.94
24h Volume:
58,531
Relative Volume:
0.47
Market Cap:
$82.62M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-1.8571
EPS:
-1.05
Net Cash Flow:
$-16.76M
1W Performance:
+3.72%
1M Performance:
+8.94%
6M Performance:
-22.00%
1Y Performance:
-36.89%
1-Day Range:
$1.8801
$1.95
1-Week Range:
$1.74
$2.00
52-Week Range:
$1.59
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
1.95 | 82.62M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
Aug Selloffs: How InspireMD Inc stock compares to growth peers2025 Institutional Moves & Daily Growth Stock Tips - moha.gov.vn
Head-To-Head Review: Biotricity (NASDAQ:BTCY) versus InspireMD (NYSE:NSPR) - Defense World
Peter A. Soukas Joins InspireMD as Chief Medical Officer - Medical Product Outsourcing
Investment Report: Will InspireMD Inc stock gain from lower inflationWeekly Stock Analysis & Reliable Price Breakout Signals - moha.gov.vn
Total debt per share of InspireMD Inc. – MUN:II2 - TradingView
InspireMD Director Paul Stuka Acquires 10,130 Shares - TradingView
Can InspireMD Inc. (II2) stock survive global slowdownM&A Rumor & High Conviction Trade Alerts - Newser
Is InspireMD Inc. (II2) stock supported by strong fundamentalsWeekly Gains Summary & Weekly Sector Rotation Insights - Newser
InspireMD (NSPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Financial Contrast: InspireMD (NYSE:NSPR) vs. Biostage (OTCMKTS:BSTG) - Defense World
Will InspireMD Inc. (II2) stock profit from fiscal stimulusWeekly Gains Report & Risk Managed Investment Entry Signals - BỘ NỘI VỤ
How InspireMD Inc. stock performs in rate cut cyclesTreasury Yields & Verified Swing Trading Watchlists - BỘ NỘI VỤ
InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results - ADVFN
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth? - Yahoo Finance
InspireMD (NYSE:NSPR) Shares Up 2%Should You Buy? - MarketBeat
InspireMD announces publication of CREST-2 data in NEJM - MSN
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
InspireMD Celebrates Positive Outcomes from CREST-2 Study Supporting Carotid Stenting for Asymptomatic Patients - Quiver Quantitative
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting - The Manila Times
Landmark CREST-2 Study Published in the New England Journal - GlobeNewswire
InspireMD announces inducement grants - Medical Buyer
InspireMD (Nasdaq: NSPR) Showcases CREST-2 NEJM Data on Lower Stroke Risk with CAS - Stock Titan
InspireMD Reports Record Revenue Amid U.S. Launch - MSN
What analysts say about InspireMD Inc stockMarket Correction Analysis & Low Entry Cost Trading - earlytimes.in
InspireMD’s Pivotal Study on CGuard Prime Stent System: A Potential Game-Changer - MSN
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
InspireMD (Nasdaq: NSPR) grants 122,054 inducement shares to eight new hires - Stock Titan
What catalysts could drive InspireMD Inc. stock higherEarnings Recap Summary & Capital Efficiency Focused Ideas - newser.com
Is InspireMD Inc. (II2) stock suitable for passive index fundsOil Prices & Capital Protection Trade Alerts - newser.com
InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Why analysts remain bullish on InspireMD Inc. stockDollar Strength & Real-Time Buy Signal Alerts - newser.com
Applying sector rotation models to InspireMD Inc.Quarterly Trade Review & Free Daily Entry Point Trade Alerts - newser.com
InspireMD (NASDAQ: NSPR) schedules fireside chat at Piper Sandler healthcare conference - Stock Titan
How InspireMD Inc. (II2) stock responds to job market shifts2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
Applying chart zones and confluence areas to InspireMD Inc.2025 Macro Impact & Daily Entry Point Trade Alerts - newser.com
Is InspireMD Inc. stock poised for growthPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
NSPR SEC FilingsInspiremd 10-K, 10-Q, 8-K Forms - Stock Titan
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):